Condition: Pemphigus Vulgaris · Sponsor: Cabaletta Bio
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
This description comes directly from the study's public registry record.
Cabaletta Bio · +1 267 759 3100 · clinicaltrials@cabalettabio.com
Always discuss trial participation with your own doctor first.
| Stanford University, Dept. of Dermatology | Redwood City, California, United States | Recruiting |
| UC Davis, Dept. of Dermatology | Sacramento, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Mount Sinai - Icahn School of Medicine | New York, New York, United States | Withdrawn |
| Columbia University | New York, New York, United States | Recruiting |
| University of North Carolina, Department of Dermatology | Chapel Hill, North Carolina, United States | Withdrawn |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| UT Southwestern Medical Center, Dept. of Dermatology | Dallas, Texas, United States | Recruiting |
| MD Anderson Texas Medical Center | Houston, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04422912